Adverse reactions to duloxetine in depression

Expert Opinion on Drug Safety

Volumn 10, Issue 6, 2011, Pages 839-850

  Bitter, Istvan ^a   Filipovits, Dora ^a   Czobor, Pal ^a,b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

Depression; Duloxetine; Safety; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTICOAGULANT AGENT; ASPARTATE AMINOTRANSFERASE; BACLOFEN; BICARBONATE; CHOLESTEROL; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; PAROXETINE; PHENELZINE; QUETIAPINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

ABNORMAL DREAMING; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY DISORDER; APGAR SCORE; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BALANCE IMPAIRMENT; BICARBONATE BLOOD LEVEL; BLEEDING; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CONSTIPATION; DECREASED APPETITE; DEMOGRAPHY; DEPERSONALIZATION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; FATIGUE; GENDER; HEADACHE; HEART PALPITATION; HEPATITIS; HUMAN; HYPERHIDROSIS; HYPERPROLACTINEMIA; HYPOMANIA; INAPPROPRIATE VASOPRESSIN SECRETION; INSOMNIA; IRRITABILITY; JAUNDICE; LACTATION; LIVER FAILURE; LIVER INJURY; MAJOR DEPRESSION; MANIA; NAUSEA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NIGHTMARE; PARESTHESIA; PATIENT COMPLIANCE; PR INTERVAL; PREGNANCY; PREMATURE LABOR; PRURITUS; PULMONARY HYPERTENSION; QRS COMPLEX; QT PROLONGATION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STRESS INCONTINENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREMOR; VITAL SIGN; VIVID DREAM; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TREATMENT OUTCOME;

EID: 80054753155     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.582037     Document Type: Review

References (105)

1. Patten SB. Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. BMC Psychiatry 2009;9:19
2. Oestergaard S, Moldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis. J Affect Disord 2010;published online 13 October 2010, doi:S0165-0327(10)00548-3
3. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;(2):CD006532
4. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58
5. Gartlehner G, Thaler K, Hansen RA, et al. The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysis. Drug Saf 2009;32:1159-73
6. Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008;149:725-33
7. Culpepper L. Why do you need to move beyond first-line therapy for major depression? J Clin Psychiatry 2010;71Suppl 1:4-9
8. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine-and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005;62:2481-90 (Pubitemid 41720564)
9. Mancini M, Perna G, Rossi A, et al. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother 2010;11:1167-81
10. McCormack PL, Keating GM. Duloxetine: in stress urinary incontinence. Drugs 2004;64:2567-73 (Pubitemid 39587220)
11. Yentreve: European Public Assessment Reports-Product Information. European Medicines Agency. Last updated: 10 February 2011. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/ 000545/human-med-001164.jsp&murl=menus/medicines/medicines.jsp&mid= WC0b01ac058001d125& jsenabled=true. [Last accessed 15 February 2011]
12. FDA clears Cymbalta to treat chronic musculoskeletal pain. FDA News Release. 2010.11.04. Available from: http://www. fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm232708.htm. Last accessed 8 February 2011
13. Cymbalta-Highlights of Prescribing Information. FDA Approved Drug Products. 2009.11.19. Available from: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/021427s030lbl.pdf. Last accessed 8 February 2011
14. Whitmyer VG, Dunner DL, Kornstein SG, et al. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry 2007;68:1921-30
15. Mancini M, Gianni W, Rossi A, et al. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opin Pharmacother 2009;10:847-60
16. Gao K, Kemp DE, Fein E, et al. Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics. J Clin Psychiatry 2010;published online 19 October 2010, doi:10.4088/JCP.09r05535gre
17. Wernicke JF, Gahimer J, Yalcin I, et al. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005;4:987-93 (Pubitemid 41671597)
18. Cymbalta: European Public Assessment Reports-Product Information. European Medicines Agency. Last updated: 10 February, 2011. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000572/WC500036781.pdf. Last accessed 12 February 2011
19. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47 (Pubitemid 41443048)
20. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27:1126-43 (Pubitemid 41393910)
21. Lobo ED, Bergstrom RF, Reddy S, et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008;47:191-202
22. Smith TR. Duloxetine in diabetic neuropathy. Expert Opin Pharmacother 2006;7:215-23 (Pubitemid 43263259)
23. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003;73:170-7 (Pubitemid 36269668)
24. Preskorn SH, Nichols AI, Paul J, et al. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract 2008;14:368-78
25. Hudson JI, Perahia DG, Gilaberte I, et al. Duloxetine in the treatment of major depressive disorder: an open-label study. BMC Psychiatry 2007;7:43
26. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. Br J Psychiatry 2006;188:346-53
27. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005;20:327-41 (Pubitemid 41093935)
28. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007;23:175-84 (Pubitemid 46191681)
29. Licinio J, Wong ML. Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Discov 2005;4:165-71 (Pubitemid 40277496)
30. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007;164:1356-63 (Pubitemid 47461135)
31. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006;26:587-94 (Pubitemid 44772735)
32. Balazs J, Benazzi F, Rihmer Z, et al. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006;91:133-8
33. Wada K, Sasaki T, Jitsuiki H, et al. Manic/hypomanic switch during acute antidepressant treatment for unipolar depression. J Clin Psychopharmacol 2006;26:512-15 (Pubitemid 44401474)
34. Dunner DL, D'Souza DN, Kajdasz DK, et al. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord 2005;87:115-19 (Pubitemid 40828210)
35. Mallinckrodt CH, Prakash A, Andorn AC, et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006;40:337-48 (Pubitemid 43668983)
36. Kornstein SG, Dunner DL, Meyers AL, et al. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry 2008;69:1383-92
37. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003;64:1237-44
38. Dunner DL, Wilson M, Fava M, et al. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety 2008;25:E1-8
39. Walton SM, Schumock GT, Lee KV, et al. Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008;28:1443-52
40. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
41. Hurley DJ, Turner CL, Yalcin I, et al. Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur J Obstet Gynecol Reprod Biol 2006;125:120-8
42. Dugan SE, Fuller MA. Duloxetine: a dual reuptake inhibitor. Ann Pharmacother 2004;38:2078-85 (Pubitemid 40169380)
43. Kelin K, Berk M, Spann M, et al. Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study. Int J Clin Pract 2010;64:719-26
44. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002;63:308-15 (Pubitemid 34456358)
45. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Psychiatry 2006;21:367-78
46. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99 (Pubitemid 38944137)
47. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo-and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004;14:457-70 (Pubitemid 39626894)
48. Mallinckrodt CH, Goldstein DJ, Detke MJ, et al. Duloxetine: a new treatment for the emotional and physical symptoms of depression. Prim Care Companion J Clin Psychiatry 2003;5:19-28
49. Nelson JC, Lu PY, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006;8:212-19 (Pubitemid 44371559)
50. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002;63:225-31 (Pubitemid 34407082)
51. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res 2008;42:22-34 (Pubitemid 47570043)
52. Hartford J, Kornstein S, Liebowitz M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007;22:167-74 (Pubitemid 46559873)
53. Cutler AJ, Montgomery SA, Feifel D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 2009;70:526-39
54. Carter NJ, McCormack PL. Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 2009;23:523-41
55. Cymbalta (Duloxetine Hydrochloride)-Warnings and Precautions. DrugLib.com Drug Information Portal. 2009.02.16. Available from: http://www.druglib.com/ druginfo/cymbalta/warnings-precautions. [Last accessed 9 April 2011]
56. Hanje AJ, Pell LJ, Votolato NA, et al. Case report: fulminant hepatic failure involving duloxetine hydrochloride. Clin Gastroenterol Hepatol 2006;4:912-17 (Pubitemid 43994541)
57. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4:281-5 (Pubitemid 351618774)
58. Norman TR, Olver JS. Duloxetine in the treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat 2008;4:1169-80
59. Goldstein DJ. Duloxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2007;3:193-209 (Pubitemid 46864059)
60. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005;25:132-40 (Pubitemid 40395091)
61. Taylor D. Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008;118:434-42
62. Clayton AH. Recognition and assessment of sexual dysfunction associated with depression. J Clin Psychiatry 2001;62 Suppl 3:5-9 (Pubitemid 32164675)
63. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94 (Pubitemid 27514710)
64. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001;62Suppl 3:10-21 (Pubitemid 32164676)
65. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259-66
66. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo-and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-92 (Pubitemid 40942413)
67. Montejo AL, Perahia DG, Spann ME, et al. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med 2011;In press
68. Englisch S, Knopf U, Scharnholz B, et al. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. J Psychopharmacol 2009;23:875-82
69. Raskin J, Wiltse CG, Dinkel JJ, et al. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder. J Clin Psychopharmacol 2008;28:32-8
70. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67Suppl 6:33-7 (Pubitemid 44078111)
71. Oelke M, Roovers JP, Michel MC. Safety and tolerability of duloxetine in women with stress urinary incontinence. BJOG 2006;113Suppl 1:22-6 (Pubitemid 43383541)
72. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 2004;4:11
73. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms. Expert Opin Drug Saf 2006;5:157-68 (Pubitemid 43056447)
74. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006;5:523-37 (Pubitemid 44468450)
75. Trivedi MH, Desaiah D, Ossanna MJ, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol 2008;23:161-9 (Pubitemid 351535907)
76. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry 2007;68:1707-16 (Pubitemid 350247500)
77. Norman TR, Olver JS. Continuation treatment of major depressive disorder: is there a case for duloxetine? Drug Des Devel Ther 2010;4:19-31
78. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003;170:1259-63 (Pubitemid 37108127)
79. Brunton S, Wang F, Edwards SB, et al. Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010;33:393-407
80. Perahia DG, Kajdasz DK, Desaiah D, et al. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005;89:207-112
81. Bailey RK, Mallinckrodt CH, Wohlreich MM, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy. J Natl Med Assoc 2006;98:437-47 (Pubitemid 43352537)
82. Lewis-Fernandez R, Blanco C, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients. J Clin Psychiatry 2006;67-1379-90
83. Tianmei S, Knadler MP, Lim MT, et al. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. Clin Pharmacokinet 2007;46:767-75 (Pubitemid 47347448)
84. Lee P, Shu L, Xu X, et al. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry Clin Neurosci 2007;61:295-307 (Pubitemid 46684004)
85. Stewart DE, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006;94:183-9 (Pubitemid 44093036)
86. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-9 (Pubitemid 46972905)
87. Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005;13:227-35 (Pubitemid 41031091)
88. Wise TN, Wiltse CG, Iosifescu DV, et al. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract 2007;61:1283-93 (Pubitemid 47052377)
89. Lobo ED, Loghin C, Knadler MP, et al. Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. Clin Pharmacokinet 2008;47:103-9
90. Desarkar P, Das A, Sinha VK. Duloxetine for childhood depression with pain and dissociative symptoms. Eur Child Adolesc Psychiatry 2006;15:496-9 (Pubitemid 46020534)
91. Meighen KG. Duloxetine treatment of pediatric chronic pain and co-morbid major depressive disorder. J Child Adolesc Psychopharmacol 2007;17:121-7 (Pubitemid 46452088)
92. Delgado SV, Saldana SN, Barzman DH, et al. Response to duloxetine in a depressed, treatment-resistant adolescent female. J Child Adolesc Psychopharmacol 2007;17:889-94 (Pubitemid 351158606)
93. Strawn JR, Whitsel R, Nandagopal JJ, et al. Atypical stevens-johnson syndrome in an adolescent treated with duloxetine. J Child Adolesc Psychopharmacol 2011;21:91-112
94. Way CM. Safety of newer antidepressants in pregnancy. Pharmacotherapy 2007;27:546-52 (Pubitemid 46536236)
95. Briggs GG, Ambrose PJ, Ilett KF, et al. Use of duloxetine in pregnancy and lactation. Ann Pharmacother 2009;43:1898-902
96. Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. Am J Psychiatry 2008;165:651 (Pubitemid 351705350)
97. Kruszewski SP. Neonatal brain injury. N Engl J Med 2005;352:839
98. Koren G, Boucher N. Adverse effects in neonates exposed to SSRIs and SNRI in late gestation-Motherisk Update 2008. Can J Clin Pharmacol 2009;16:e66-7
99. Tuccori M, Testi A, Antonioli L, et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009;31 Pt 1:1426-53
100. Rampono J, Simmer K, Ilett KF, et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009;42:95-100
101. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007;27:607-13 (Pubitemid 351339448)
102. Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf 2005;28:137-52 (Pubitemid 40321769)
103. Menchetti M, Gozzi BF, Saracino MA, et al. Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines. World J Biol Psychiatry 2009;10:385-9
104. Paulzen M, Hiemke C, Grunder G. Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. Int J Neuropsychopharmacol 2009;12:1431-2
105. Vey EL, Kovelman I. Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey. J Forensic Leg Med 2010;17:175-85